Prof sarman Singh

Professor,  Medical Science Education and Research Center, IISER, Bhopal, India 

Location: India


Recently Online

Consulting Services


Areas Of Interest

Microbiology Infection and Infestation Tubercular Meningitis Antibiotic Editorial Comment Grants Manuscript, Medical Toxoplasma gondii Leishmania Corona, Protein Mycobacterium Hepatitis Laboratories Diagnostic Equipments Molecular Biology

Professional Narrative


Employment

Director, All India Institute of Medical Sciences, Bhopal 2018
Professor & Head, All India Institute of Medical Sciences, New Delhi 2007
Additional Professor, All India Institute of Medical Sciences, New Delhi 1999
Associate Professor, All India Institute of Medical Sciences, New Delhi 1995
Assistant Professor, All India Institute of Medical Sciences, New Delhi 1990
Consultant-HIV/AIDS, Safe Blood transfusion, World Health Organization, New Delhi 1999

Education

MD (Doctor of Medicine), Post Graduate Institute of Medical Education and Research, Chandigarh 1985
Diploma Hospital Administration, YMCA, New Delhi 1984
MBBS (Bachelor of Medicine and Surgery), King George Medical College, Lucknow 1977
Bachelor of Science (BSc.), Agra University (Now Dr Bhimrao Ambedkar University), Agra 1974

Referees

Prof. NK Mehra, All India Institute of Medical Sciences, New Delhi.

“Former Dean Research”


Dr. VM Katoch, Indian Council of Medical Research, New Delhi.

“Former Director-General”


Publications

1. Lisco A, Munawwar A, Introini A, Vanpouille C, Saba E, Feng X, Grivel JC, Singh S*, Margolis L. Semen of HIV-1 Infected individuals: local shedding of Herpes viruses and Reprogrammed Cytokine Network. J Infect Dis. 2012; 205 (1): 97-105. ( IF: 6.2)

2. Kumar V, Yadav VK, Hassan I, Singh AK, Dey S, Singh S, Singh TP, Yadav S. Kinetic and Structural Studies on the Interactions of Heparin and Proteins of Human Seminal Plasma using Surface Plasmon Resonance.Protein Pept Lett. 2012; 19 (8):795- 803. (IF: 1.07)

3. Tomar AK, Sooch BS, Singh S, Yadav S. Quantification studies in human seminal plasma samples identify prolactin inducible protein as a plausible marker of azoospermia. Biomarkers. 2012; 17 (6): 545-51. ( IF: 2.2)

4. Tomar AK, Sooch BS, Singh S, Yadav S. Differential proteomics of human seminal plasma: A potential target for searching male infertility marker proteins. Proteomics Clin Appl. 2012; 6:147-51. ( IF: 2.96)

5. Price P, Haddow LJ, Affandi J, Agarwal U, Easterbrook PJ, Elliott J, French M, Kumar M, Moosa MY, Oliver B, Singh S, et al. Plasma Levels of Vitamin D in HIV Patients Initiating Antiretroviral Therapy Do Not Predict Immune Restoration Disease Associated with Mycobacterium tuberculosis.AIDS Res Hum Retroviruses. 2012; 28 (10) 1216-9. (IF: 2.58)

6. Kumar S, Tomar AK, Singh S, Saraswat M, Singh S*, Singh TP, Yadav S. Human serum albumin as a new interacting partner of prolactin inducible protein in human seminal plasma.Int J BiolMacromol. 2012; 50(2):317-22. (IF: 2.858)

7. Munawwar A, Singh S*. AIDS associated Tuberculosis: a catastrophic collision to evade the host immune system. Tuberculosis. 2012; 92 (5):348-7. [DOI: 10.1016/j.tube.2012.05.006] (IF: 3.5)

8. Singh S*, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N. Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 3: Colorimetric Redox Indicator Assay v1.3.12. J Lab Physicians. 2012 Jul; 4(2):120-6.

9. Singh S*, Kumar P, Sharma S, Mumbowa F, Martin A, DurierN.Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 2: Nitrate Reductase Assay v1.3.12. J Lab Physicians. 2012 Jul; 4(2):112-9.

10. Singh S*, Kumar P, Sharma S, Mumbowa F, Martin A, Durier N.Rapid Identification and Drug Susceptibility Testing of Mycobacterium tuberculosis: Standard Operating Procedure for Non-Commercial Assays: Part 1: Microscopic Observation Drug Suceptibility Assay v2.4.12. J Lab Physicians. 2012 Jul; 4(2):101-11.

11. Singh S*, Singh, J, Kumar S, Gopinath K, Balooni V, Singh N, Mani K. Poor Performance of Serological Tests in the Diagnosis of Pulmonary Tuberculosis: Evidence from a Contact Tracing Field Study. PLoS ONE 2012. http://dx.plos.org/10.1371/journal.pone.0040213 (IF: 3.78)

12. Lagrange PH, Thangaraj SK, Dayal R, Despande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, et al. A toolbox for tuberculosis diagnosis: an Indian multicentric study (2006-2008) microbiological result. PLoS One. 2012; 7(8):e43739. Doi: 10.1371/journal.pone.0043739. (IF: 3.78)

13. Nandan D; Bhatt GC; DewanV; Yadav TP; Singh S*. Isolated tuberculous liver abscess in a 3-year old immunocompetent child. Paediatr Int Child Health. 2013; 33(3): 187- 189.(IF: 1.08)

14. Jayakumar R., Joshi YK, Singh S*. Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir. J Lab Physicians 2012; 4(1):10-6.

15. Kumar V, Yadav VK, Hassan I, Singh AK, Dey S, Singh S, Singh TP, Yadav S. Kinetic and Structural Studies on the Interactions of Heparin and Proteins of Human Seminal Plasma using Surface Plasmon Resonance.Protein Pept Lett. 2012; 19(8):795- 803. (IF: 1.98)

16. Lagrange PH , Thangaraj SK, Dayal R , Despande A, Ganguly NK, Girardi E, Joshi B , Katoch K , Katoch VM , Kumar M, Lakshmi V, Leportier M , Longuet C, Subbalaxmi V. S. M, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BSA, Vernet G, Goletti D. A Toolbox for Tuberculosis Diagnosis: An Indian Multicentric Study (2006-2008): Microbiological Results. PLoS ONE 2012; 7(8): e43739. doi:10.1371/journal.pone.0043739 (IF: 3.78)

17. Singh S*, Sankar MM, Kumar M, Sharma SK, Disseminated Tuberculosis Caused by a Rare and Multidrug Resistant “Beijing” Genotype of Mycobacterium tuberculosis. Chest, 2012; 142: 253A-253A. doi:10.1378/chest.1388948 (IF: 5.08)

18. Magee MJ, Blumberg HM, Broz D, Furner SE, Samson L, Singh S, Hershow RC. Prevalence of drug resistant tuberculosis among patients at high risk for HIV attending out patient clinics in Delhi, India. Southeast Asian J Trop Med Public Health. 2012; 43(2):354-63.

19. Lisco A, Introini A, Munawwar A, Vanpouille C, Grivel JC, Blank P, Singh S*, Margolis L. HIV-1 imposes rigidity on Blood and semen cytokine network. Am J Reprod Immunol. 2012; 68 (6): 515-21. Doi: 10.1111/aji.12015. (IF: 3.08)

20. Chhikara N, Saraswat M, Tomar AK, Dey S, Singh S, et al. Human Epididymis Protein-4 (HE-4): A Novel Cross-Class Protease Inhibitor. PLoS ONE 2012; 7(11): e47672. doi:10.1371/journal.pone.0047672 (IF: 3.78)

21. Tomar AK, Sooch BS, Raj I, Singh S, Yadav S. Interaction analysis identifies semenogelin I fragments as new binding partners of PIP in human seminal plasma. Int J Biol Macromol. 2013; 52: 296-99 doi: 10.1016/j.ijbiomac.2012.10.011. (IF: 2.85)

22. Sankar MM, Balooni V, Singh J, Singh S*. Diagnostic performance of commercially available enzyme-linked immunosorbent assay kit in the diagnosis of extrapulmonary tuberculosis. J Lab Physicians. 2013 Jan; 5(1):11-6. Doi: 10.4103/0974-2727.115902.

23. Singh N, Mishra J, Singh R, Singh S*. Animal Reservoirs of Visceral Leishmaniasis in Bihar, India. J Parasitol. 2013; 99: 64-7. (IF: 1.5) 24. Sankar MM, Kumar P, Munawwar A, Kumar M, Singh J, Singh A, Parashar D, Malhotra N, Duttagupta S, Singh S*. Usefulness of multiplex PCR in the diagnosis of genital tuberculosis in females with infertility. Eur J Clin Microbiol Infect Dis. 2013; 32(3):399-405 PMID:23052988 (IF: 3.18)

25. Mishra J, Madhubala R, Singh S*. Visceral and Post Kala-Azar Dermal Leishmaniasis isolates show significant difference in their in-vitro drug susceptibility pattern. Parasitology Research. 2013; 112(3):1001-9. (IF: 2.18)

26. Tomar AK, Sooch BS, Singh S, Yadav S. Aggregation analysis of Con a binding proteins of human seminal plasma: A dynamic light scattering study. Int J BiolMacromol. 2013; 53:133-7. (IF: 2.85)

27. Bhatt GC, Nandan D, Singh S. Isolated tuberculous liver abscess in immunocompetent children-Report of two cases. Pathog & Glob Health. 2013; 107(1):35-37. doi:10.1179/2047773212Y.0000000071 (IF: 0.85)

28. Jain S, Singh S, Sankar MM, Saha R, Rangaraju RR, Chugh TD. Catheter-related bacteremia due to M. chelonae in an immunocompromised patient: an emerging nosocomial pathogen. Indian J Med Microbiol. 2012; 30(4):489-91. (IF: 1.05)

29. Yadav VK, Chhikara N, Gill K, Dey S, Singh S, Yadav S. Three low molecular weight cysteine proteinase inhibitors of human seminal fluid: Purification and enzyme kinetic properties. Biochimie. 2013; 95(8):1552-59. Doi: pii: S0300-9084(13)00111-9. (IF: 3.123)

30. Yadav VK, Saraswat M, Chhikara N, Singh S, Yadav S. Heparin and heparin Binding proteins: potential relevance to reproductive physiology. Curr Protein Pept Sci. 2013 Feb 1; 14(1):61-9. (IF: 3.10)

31. Mathur P, Singh S*. Multidrug Resistance in Bacteria: A Serious Patient Safety Challenge for India. J Lab Physicians. 2013 Jan; 5(1):5-10.

32. Kumar P, Singh A, Sharma U, Singh D, Dobhal MP, Singh S*. Anti-mycobacterial activity of plumericin and isoplumericin against MDR Mycobacterium tuberculosis. PulmPharmacolTher. 2013 Jun; 26(3):332-5. (IF: 2.563)

33. Tomar AK, Sooch BS, Raj I, Singh S, Yadav S. Interaction analysis identifies semenogelin I fragments as new binding partners of PIP in human seminal plasma. Int J BiolMacromol. 2013; 52:296-9. (IF: 2.85)

34. Sankar MM, Singh J, Diana SC, Singh S*. Molecular characterization of Mycobacterium tuberculosis isolates from North Indian patients with extra-pulmonary tuberculosis. Tuberculosis (Edinb). 2013; 93(1):75-83. (IF: 3.5)

35. Mishra J, Dey A, Singh N, Somvanshi R, Singh S*. Evaluation of toxicity and therapeutic efficacy of a new liposomal formulation of Amphotericin B in mice model by real time PCR. Indian J Med Res. 2013; 137: 767-776. (IF: 2.05)

36. Singh J, Sankar MM, Kumar S, Gopinath K, Singh N, Mani K, Singh S*. Incidence and prevalence of tuberculosis among household contacts of pulmonary tuberculosis patients in a Peri-urban population of South Delhi, India. PLoS One. 2013; 8 (7) e69730. doi:10.1371/journal.pone.0069730. (IF: 3.785)

37. Das S, Roychowdhury T, Kumar P, Kumar A, Kalra P, Singh J, Singh S, Prasad H, Bhattacharya A. Genetic Heterogeneity revealed by sequence analysis of Mycobacterium tuberculosis isolates from extra-pulmonary tuberculosis patients. BMC Genomics, 2013: June 17: 14 (1): 404. (IF: 5.85)

38. Yadav VK, Saraswat M, Chhikara N, Singh S, Yadav S. Heparin and heparin binding proteins: potential relevance to reproductive physiology. Curr Protein Pept Sci. 2013 Feb; 14(1):61-9. (IF: 3.10)

39. Mishra J, Madhubala R, Singh S*. Visceral and post-Kala-Azar dermal leishmaniasis isolates show significant difference in their in vitro drug susceptibility pattern. Parasitol Res. 2013 Mar; 112(3):1001-9. Doi: 10.1007/s00436-012-3222-1. Epub 2012 Dec 18. (IF: 2.15)

40. Oliver BG, HaddowLJ, Agarwal U, Kumar M, Easterbrook PJ, Moosa MY, Singh S, Price P. Pre-antiretroviral therapy plasma levels of CCL2 may aid in the prediction of tuberculosis-associated immune reconstitution inflammatory syndrome in HIV patients after they commence antiretroviral therapy. J Acquir Immune DeficSyndr. 2013 Jun 1;63(2):e72-4. doi: 10.1097/QAI.0b013e31828e6182. (IF: 4.556)

41. Affandi JS, Kumar M, Agarwal U, Singh S, Price P. The search for a genetic factor associating with immune restoration disease in HIV patients co-infected with Mycobacterium tuberculosis. Dis Markers. 2013; 34(6):445-9. Doi: 10.3233/DMA130991. (IF: 2.65)

42. Parashar D, Kabra SK, Lodha R, Singh V, Mukherjee A, Arya T, Grewal HM, Singh S*; Delhi Pediatric TB Study Group. Does neutralization of gastric aspirates from children with suspected intrathoracic tuberculosis affect mycobacterial yields on MGIT culture? J Clin Microbiol. 2013 Jun;51(6):1753-6. doi: 10.1128/JCM.00202-13. (IF: 4.115)

43. Kumar P, Rufai SB, Singh S*. Heat fixed but unstained slide smears are infectious to laboratory staff. Indian J Tuberc. 2013 Jul;60(3):142-6.

44. Singh S*. Bio-safety precautions in tuberculosis laboratory. Indian J Tuberc. 2013 Jul; 60(3):135-7.

45. Yadav VK, Chhikara N, Gill K, Dey S, Singh S. Yadav S. Three low molecular weight cysteine proteinase inhibitors of human seminal fluid: purification and enzyme kinetic properties. Biochimie. 2013 Aug;95(8):1552-9. doi: 10.1016/j.biochi.2013.04.007. (IF: 3.15)

46. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, MalladiSV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S. Sodha A, Kabeer BS, Vernet G, Goletti D. A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006-2008). Evaluation of QuantiFERON-TB gold in tube for TB diagnosis. PLoS One. 2013 Sep 6;8(9):e73579. doi: 10.1371/journal.pone.0073579. (IF: 3.57)

47. Mishra J, Singh S*. Miltefosine resistance in Leishmania donovani involves suppression of oxidative stress-induced programmed cell death. Exp Parasitol. 2013;135(2):397-406. doi:10.1016/j.exppara.2013.08.004. (IF: 2.15)

48. Mukherjee A, Singh S, Lodha R, Singh V, Hesseling AC, Grewal HM, Kabra SK; Delhi Pediatric TB Study Group. Ambulatory Gastric Lavages Provide Better Yields of Mycobacterium tuberculosis Than Induced Sputum in Children with Intrathoracic Tuberculosis. Pediatr Infect Dis J. 2013 Dec;32(12):1313-7. doi: 10.1097/INF.0b013e31829f5c58. (IF: 2.75)

49. Mukherjee A, Saini S, Kabra SK, Gupta N, Singh V, Singh S, Bhatnagar S, Saini D, Grewal HM, Lodha R; Delhi TB Study group. Effect of micronutrient deficiency on QuantiFERON-TB Gold In-Tube test and tuberculin skin test in diagnosis of childhood intrathoracic tuberculosis. Eur J Clin Nutr. 2014 Jan;68(1):38-42. doi: 10.1038/ejcn.2013.216. (IF: 2.95)

50. Singh S*. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. eBMJ 2014;348:g3656

51. Kumar P, Balooni V, Sharma BK, Kapil V, Sachdeva KS, Singh S*. High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis (Edinb). 2014 Jan;94(1):73-80. doi: 10.1016/j.tube.2013.10.001. (IF: 3.5)

52. Singh S*, Munawwar A, Rao S, Mehta S, Hazarika NK. Serologic prevalence of Toxoplasma gondii in Indian women of child bearing age and effects of social and environmental factors. PLoSNegl Trop Dis. 2014 Mar 27;8(3):e2737. doi: 10.1371/journal.pntd.0002737 (IF: 4.45)

53. Behera B, Mathur P, Bhardwaj N, Jain N, Misra MC, Kapil A, Singh S. Antibiotic susceptibilities, streptococcal pyrogenic exotoxin gene profiles among clinical isolates of group C or G Streptococcus dysgalactiae subsp. equisimilis & of group G Strep. anginosus group at a tertiary care centre. Indian J Med Res. 2014 Mar; 139(3):438-45. (IF: 1.85)

54. Mathur P, Bhardwaj N, Mathur K, Behera B, Gupta G, Kapil A, Singh S. Clinical and molecular epidemiology of beta-haemolytic streptococcal infections in India. J Infect Dev Ctries. 2014; 8 (3): 297-303. (IF: 1.55)

55. Jain S, Sankar MM, Sharma N, Singh S, Chugh TD. High prevalence of nontuberculous mycobacterial disease among non-HIV infected individuals in a TB endemic country--experience from a tertiary center in Delhi, India. Pathog Glob Health. 2014 Mar;108(2):118-22. doi: 10.1179/2047773214Y.0000000133. (IF: 1.05)

56. Satyaraddi A, Velpandian T, Sharma SK, Vishnubhatla S, Sharma A, Sirohiwal A, Nakharia GK, Sinha S, Biswas A, Singh S*. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity. Int J Tub Lung Dis, 2014; 18 (2): 188-195. (IF: 2.35)

57. Singh A, Gopinath K, Singh N, Singh S*. Deciphering the sequential events during invivo acquisition of drug resistance in Mycobacterium tuberculosis. Int J Mycobacteriol 2014; 3 (1): 36-40.

58. Singh S*. Commentary: Slow or long term on-progressor HIV patients: Indian scenario. Indian J Med Microbiol 2014; 32 (1): 77-78. (IF: 1.85)

59. Kumar P, Benny P, Jain M, Singh. Comparison of an in-house multiplex PCR with two commercial immunochromatographic tests for rapid identification and differentiation of MTB from NTM isolates. Int J Mycobacteriol 2014; 3 (1): 50-56.

60. Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A Toolbox for Tuberculosis (TB) Diagnosis: An Indian Multi-Centric Study (2006-2008); Evaluation of Serological Assays Based on PGL-Tb1 and ESAT-6/CFP10 Antigens for TB Diagnosis. PLoS One. 2014 May 5;9(5):e96367. doi: 10.1371/journal.pone.0096367. (IF: 3.77)

61. Rufai SB, Kumar P, Singh A, Prajapati S, Balooni V, Singh S*. Comparison of Xpert MTB/RIF with Line Probe Assay for Detection of Rifampin-Monoresistant Mycobacterium tuberculosis. J Clin Microbiol. 2014 Jun;52(6):1846-52. doi: 10.1128/JCM.03005-13. (IF: 4.232)

62. Nandan D, Nag VK, Trivedi N, Singh S*. X-linked Hyper-IgM Syndrome with Bronchiectasis. J Lab Physicians. 2014 Jul;6(2):114-6. doi: 10.4103/0974-2727.141510.

63. Singh S*, Rufai SB, Kumar P, Singh J. Reply to "molecular diagnosis of rifampinmonoresistant tuberculosis in Indian patients: problems with a discordance analysis". J Clin Microbiol. 2014 Sep;52(9):3504-5. doi: 10.1128/JCM.01731-14. (IF: 4.2325)

64. Nandan D, Jahan A, Dewan V, Singh S, Buxi G. Pure red cell aplasia in a threemonths-old infant possibly secondary to cytomegalo virus infection. Indian J Hematol Blood Transfus. 2014 Sep;30 (Suppl 1):30-2. doi: 10.1007/s12288-012-0226-z. (IF: 0.05)

65. Khandelwal D, Gupta N, Mukherjee A, Lodha R, Singh V, Grewal HM, Bhatnagar S, Singh S, Kabra SK; Delhi Pediatric TB Study Group. Vitamin D levels in Indian children with intrathoracic tuberculosis. Indian J Med Res. 2014 Oct;140(4):531-7. (IF: 1.85)

66. Lodha R, Mukherjee A, Singh V, Singh S, Friis H, Faurholt-Jepsen D, Bhatnagar S, Saini S, Kabra SK, Grewal HM; Delhi Pediatric TB Study Group. Effect of micronutrient supplementation on treatment outcomes in children with intrathoracic tuberculosis: a randomized controlled trial. Am J Clin Nutr. 2014 Nov;100(5):1287-97. (IF: 6.95)

67. Singh S*. Early detection of multi-drug resistant tuberculosis in India using GenoTypeMTBDRplus assay & profile of resistance mutations in Mycobacterium tuberculosis. Indian J Med Res. 2014 Oct;140(4):477-9. (IF: 1.85)

68. Kumar P, Pandya D, Singh N, Behera D, Aggarwal P, Singh S*. Loop-mediated isothermal amplification assay for rapid and sensitive diagnosis of tuberculosis. J Infect. 2014 Dec; 69(6):607-15. doi: 10.1016/j.jinf.2014.08.017. (IF: 4.55)

69. Mathew JL, Vijayasekharan D, Singh S*. Is Xpert MTB/RIF assay in gastric lavage aspirate useful for diagnosis of smear-negative childhood pulmonary tuberculosis? Indian Pediatr. 2014 Dec; 51(12):1007-11. (IF: 1.10)

70. Singh S*. Changing trends in the epidemiology, clinical presentation, and diagnosis of Leishmania-HIV co-infection in India. Int J Infect Dis. 2014 Dec; 29:103-12. doi: 10.1016/j.ijid.2014.07.011. (IF: 2.15)

71. Munawwar A, Sharma SK, Gupta S, Singh S*. Seroprevalence and determinants of Kaposi sarcoma-associated human herpesvirus 8 in Indian HIV-infected males. AIDS Res Hum Retroviruses. 2014 Dec;30(12):1192-6. doi: 10.1089/aid.2014.0184. (IF: 2.33)

72. Yadav VK, Mandal RS, Puniya BL, Singh S, Yadav S. Studies on the interactions of SAP-1 (an N-terminal truncated form of cystatin S) with its binding partners by CDspectroscopic and molecular docking methods. J Biomol Struct Dyn. 2015; 33(1):147- 57. (IF: 2.69)

73. Singh A, Gopinath K, Sharma P, Bisht D, Sharma P, Singh N, Singh S*. Comparative proteomic analysis of sequential isolates of Mycobacterium tuberculosis from a patient with pulmonary tuberculosis turning from drug sensitive to multidrug resistant. Indian J Med Res 2015; 141 (1): 27-45. (IF: 1.60)

74. Pal R, Hameed S, Kumar P, Singh S, Fatima Z. Comparative Lipidome Profile of Sensitive and Resistant Mycobacterium tuberculosis Strain. Int J Curr Microbiol App Sci.2015; 1: 189-197.

75. Singh S*, Dey B, Sachdeva KS, Kabra SK, Chopra KK, Chaudhary VK, Sharma P, Katoch VM. Challenges in tuberculosis diagnosis and management: recommendations of the expert panel. J Lab Physicians. 2015 Jan-Jun;7(1):1-3. doi: 10.4103/0974- 2727.154778.

76. Singh S*, Kumar M, Singh P. Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker? Tuberc Res Treat. 2015; 2015:957519. doi: 10.1155/2015/957519.

77. Nag VK, Nandan D, Singh S, Arora SK, Tsanglao W, Arya N. Pulmonary Tuberculosis: A Predominant Cause of Childhood Bronchiectasis in India. J Commun Dis 2015; 47 (1): 14-18.

78. Yadav VK, Mandal RS, Puniya BL, Kumar R, Dey S, Singh S, Yadav S. Structural and binding studies of SAP-1 protein with heparin. Chem Biol Drug Des. 2015 Mar; 85(3):404-10. doi: 10.1111/cbdd.12420. (IF: 2.485)

79. Singh S*. EPTB in Disdain: Indian Public Health Scenario. Eradicating TB in India. Global Policy, 2015; 3 (Spl): 56-61.

80. Kumar P, Kumar P, Balooni V, Singh S*. Genetic mutations associated with rifampicin and isoniazid resistance in MDR-TB patients in North-West India. Int J Tuberc Lung Dis. 2015;19(4):434-9. (IF: 2.85)

81. Greenland K, Dixon R, Khan SA, Gunawardena K, Kihara JH, Smith JL, Drake L, Makkar P, Raman S, Singh S, Kumar S. The epidemiology of soil-transmitted helminths in Bihar State, India. PLoSNegl Trop Dis. 2015 May 20;9(5):e0003790. doi: 10.1371/journal.pntd.0003790. (IF: 4.446)

82. Sharma VK, Pai G, Deswarte C, Lodha R, Singh S, Kang LW, Yin CC, Casanova JL, Bustamante J, Kabra SK. Disseminated Mycobacterium avium complex infection in a child with partial dominant interferon gamma receptor 1 deficiency in India. J Clin Immunol. 2015 Jul;35(5):459-62. doi: 10.1007/s10875-015-0173-1. (IF: 3.15)

83. Gupta AK, Srivastava S, Singh A, Singh S*. De Novo Whole-Genome Sequence and Annotation of a Leishmania Strain Isolated from a Case of Post-Kala-Azar Dermal Leishmaniasis. Genome Announc. 2015 Jul 16;3(4). pii: e00809-15. doi: 10.1128/genomeA.00809-15.

84. Singh S*. Can Establishment of Human Microbiome be Customized after Birth with Local Traditions of First Feed and Intimate Kissing? J Lab Physicians. 2015 JulDec;7(2):73-4. doi: 10.4103/0974-2727.163140.

85. Singh J, Sankar MM, Kumar P, Couvin D, Rastogi N, Singh S*; Indian TB Diagnostics Network. Genetic diversity and drug susceptibility profile of Mycobacterium tuberculosis isolated from different regions of India. J. Infect. 2015 Aug;71(2):207-19. doi: 10.1016/j.jinf.2015.04.028. Epub 2015 Apr 29. (IF: 4.45)

86. Rufai SB, Singh A, Kumar P, Singh J, Singh S*. Performance of Xpert MTB/RIF assay in the diagnosis of pleural tuberculosis using pleural fluid samples. J Clin Microbiol. 2015 Nov;53(11):3636-8. doi: 10.1128/JCM.02182-15. (IF: 4.232)

87. Singh S*, Singh A, Prajapati S, Kabra SK, Lodha R, Mukherjee A, Singh V, Hesseling AC, Grewal HM; Delhi Pediatric TB study group. Xpert MTB/RIF assay can be used on archived gastric aspirate and induced sputum samples for sensitive diagnosis of paediatric tuberculosis. BMC Microbiol. 2015 Sep 29; 15:191. doi: 10.1186/s12866- 015-0528-z. (IF: 2.79)

88. Rabodoarivelo MS, Imperiale B, Andrianiavomikotroka R, Brandao A, Kumar P, Singh S,Ferrazoli L, Morcillo N, Rasolofo V, Palomino JC, Vandamme P, Martin A. Performance of Four Transport and Storage Systems for Molecular Detection of Multidrug-Resistant Tuberculosis. PLoS One. 2015;10(10):e0139382. doi: 10.1371/journal.pone.0139382. (IF: 3.57)

89. Drake LJ, Singh S, Mishra CK, Sinha A, Kumar S, Bhushan R, Hollingsworth TD, Appleby LJ, Kumar R, Sharma K, Kumar Y, Raman S, Chakrabarty S, Kihara JH, Gunawardena NK, Hollister G, Kumar V, Ankur A, Prasad B, Ramachandran S, Fishbane A, Makkar P. Bihar's Pioneering School-Based Deworming Programme: Lessons Learned in Deworming over 17 Million Indian School-Age Children in One Sustainable Campaign. PLoSNegl Trop Dis. 2015, 19;9(11):e0004106. doi: 10.1371/journal.pntd.0004106. (IF: 4.05)

90. Goel V, Kumar D, Kumar R, Mathur P, Singh S*. Community Acquired Enterococcal Urinary Tract Infections and Antibiotic Resistance Profile in North India. J Lab Physicians. 2016 Jan-Jun;8(1):50-4. doi: 10.4103/0974-2727.176237.

91. Munawwar A, Singh S*. Human Herpesviruses as co-pathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression. J Lab Physicians. 2016;8(1):5-18. doi: 10.4103/0974-2727.176228.

92. Saraswat M, Joenväärä S, Tomar AK, Singh S, Yadav S, Renkonen R. NGlycoproteomics of Human Seminal Plasma Glycoproteins. J Proteome Res. 2016 Mar 4;15(3):991-1001. doi: 10.1021/acs.jproteome.5b01069. (IF: 4.17).

93. Jenum S, Dhanasekaran S, Lodha R, Mukherjee A, Kumar Saini D, Singh S, Singh V, Medigeshi G, Haks MC, Ottenhoff TH, Doherty TM, Kabra SK, Ritz C, Grewal HM. Approaching a diagnostic point-of-care test for paediatric tuberculosis through evaluation of immune biomarkers across the clinical disease spectrum. Nature Sc Rep, 2016 Jan 4;6:18520. doi: 10.1038/srep18520.(IF: 5.55).

94. Srivastava S, Shankar P, Mishra J, Singh S*. Possibilities and challenges for developing a successful vaccine for leishmaniasis. Parasite & Vectors. 2016 May 12; 9(1):277. (IF: 3.51).

95. Prajapati S, Upadhyay K, Mukherjee A, Kabra SK, Lodha R, Singh V, Grewal HM, Singh S*; Delhi Pediatric TB Study Group. High prevalence of primary drug resistance in children with intrathoracic tuberculosis in India. Paediatr Int Child Health. 2016; 36(3), 214-218 (IF: 1.05).

96. Singh S*. Congenital Toxoplasmosis: Clinical features, outcomes, treatment and prevention. Trop. Parasitol. 2016; 6(2): 113-122.

97. Tomar AK, Kumar S, Chhillar S, Kumaresan A, Singh S, Yadav S. Human Serum Albumin and Prolactin Inducible Protein Complex Enhances Serum Capacitation inVitro. J Proteins & Proteomics 2016; 7 (2), 107-113.

98. Goel V, Kumar D, Patwardhan V, Balooni V, Singhal S, Singh S. Trends of Seroprevalence. Epidemiology and Clincal presentation of HIV in North India: A tertiary Care Hospita Based Study. World J AIDS 2016; 6 (02), 54-58. (IF: 0.79).

99. Jenum, S., Bakken, R., Dhanasekaran, S., Mukherjee, A., Lodha, R., Singh, S., et al. BLR1 and FCGR1A transcripts in peripheral blood associate with the extent of intrathoracic tuberculosis in children and predict treatment outcome. Nature Sc Rep, 2016; 6, 38841. http://doi.org/10.1038/srep38841(IF: 5.55).

100. Goel V, Kumar D, Raghavendra L, Singh S*. Occurrence of Needlestick and Injuries among Health-care Workers of a Tertiary Care Teaching Hospital in North India. J Lab Physicians 2017; 9 (1), 20-25. (IF: 0.67).

101. Rufai SB, Singh S*, Singh A, Kumar P, Singh J, Vishal A. Performance of Xpert MTB/RIF on Ascitic Fluid Samples for Detection of Abdominal Tuberculosis. J Lab Physicians 2017; 9 (1), 47-52. (IF: 0.67).

102. Saraswat M, Joenväärä S, Jain T, Tomar AK, Sinha A, Singh S, Yadav S, Renkonen R. Human spermatozoa quantitative proteomic signature classifies normo-and asthenozoospermia. Mol & Cell Proteomics 2017; 16 (1), 57-72. (IF: 5.91).

103. Raj V, Gupta V, Pathak M, Sreenivas V, Sood S, Singh S, Verma KK, Khanna N, Das BK, Gupta S. What puts them at risk? A cross-sectional case-control survey of demographic profile and sexual behaviour of patients with sexually transmitted infections at a tertiary care center in North India. Indian J STD AIDS, 2017; 38(1):22- 36. DOI:10.4103/0253-7184.196885. (IF: 0.431).

104. Srivastava S, Mishra J, Gupta AK, Singh A, Mishra PS, Singh S*. Laboratory Confirmed Miltefosine Resistant Cases of Visceral Leishmaniasis from India. Parasites & Vectors, 2017; 10:49 DOI 10.1186/s13071-017-1969-z (IF: 3.41).

105. Singh A, Gupta A, Gopinath K, Sharma P, Singh S*. Evaluation of 5 Novel protein biomarkers for the rapid diagnosis of pulmonary and extra-pulmonary tuberculosis: preliminary results. Nature Sc Rep, 2017; 7:44121 (1-10). DOI: 10.1038/srep44121 (IF: 5.55).

106. Rufai SB, Singh A, Singh J, Kumar P, Sankar MM Singh S*. Diagnostic usefulness of Xpert MTB/RIF assay for detection of tuberculous meningitis using cerebrospinal fluid. J Infection. 2017; 75(2): 125-131. doi.org/10.1016/j.jinf.2017.04.010(IF: 4.441).

107. Wattal W, Javeri Y, Goel N, Dhar N, Saxena S, Singh S, Oberoi JK, et al. Convergence of Minds: For better patient outcome in intensive care unit infections. Indian J Crit Care Med 2017; 21, 154-159. (IF: 0.76).

108. Kumar P, Vats O, Kumar D, Singh S*. Coccidian intestinal parasites among immunocompetent children presenting with diarrhoea: Are we missing them? Trop Parasitol 2017; 7:37-40

109. Gupta AK, Singh A, Srivastava S, Singh S*. Visceral Leishmaniasis in Children: Diagnosis, Treatment, and Prevention. J Pediatr Infect Dis, July 2017;12(4):214-221.

110. Patwardhan V, Kumar D. Goel V, Singh S*. Parasitic Infections in Pediatric Population of India: Epidemiology, Diagnosis, and Strategies for Prevention. J Pediatr Infect Dis, 2017; 12(4):228-237.

111. Patwardhan V, Singh S*. Fosfomycin for the treatment of drug-resistant urinary tract infections: potential of an old drug not explored fully. Int Urol Nephrol. 2017 Jun 14. doi: 10.1007/s11255-017-1627-6. (IF: 1.56).

112. Bhatnagar M, Sarkar N, Gandharv N, Apang O, Singh S, Ghosal S. Evaluation of antimycobacterial, leishmanicidal and antibacterial activity of three medicinal orchids of Arunachal Pradesh, India. BMC Complement Altern Med. 2017 Aug 1;17(1):379. doi: 10.1186/s12906-017-1884-z. (IF: 2.228).

113. Patwardhan V, Kumar D. Goel V, Singh S*. Changing prevalence and antibiotic drug resistance pattern of pathogens seen in community-acquired pediatric urinary tract infections at a tertiary care hospital of North India. J Lab physicians 2017; 9(4):264- 268. . (IF: 0.67).

114. Pal R, Hameed S, Kumar P, Singh S, Fatima Z. Comparative lipidomics of drug sensitive and resistant Mycobacterium tuberculosis reveals altered lipid imprints. 3Biotech, 2017; 7:335.DOI: 10.1007/s13205-017-0972-6. (IF: 1.37).

115. Singh S*, Sankar MM. Diagnostic algorithms for low-volume CSF samples in tuberculous meningitis. Lancet Inf Dis, 2017; 17 (12): 1236-37. doi: 10.1016/S1473- 3099(17)30639-4. (IF: 19.87).

116. Rufai, S.B., Singh, J., Kumar P., Mathur P., and Singh S*. Association of gyrA and rrs gene mutations detected by MTBDRslV1 on Mycobacterium tuberculosis strains of diverse genetic background from India. Nature Scientific Reports. June 2018;8(1) DOI: 10.1038/s41598-018-27299-z. (IF: 5.55).

117. Pal R, Hameed S, Sabareesh V, Kumar P, Singh S, Fatima Z. Investigations into Isoniazid Treated Mycobacterium tuberculosis by Electrospray Mass Spectrometry Reveals New Insights into Its Lipid Composition. J Pathog. Jun 19;2018:1454316. doi: 10.1155/2018/1454316. eCollection 2018

118. Munawwar, A., Gupta, S., Sharma, S.K, and Singh, S*. Seroprevalence of HSV-1 and 2 in HIV-infected males with and without GUD: Study from a tertiary care setting of India. J Lab Physicians. 2018 Jul-Sep;10(3):326-331. doi: 10.4103/JLP.JLP_7_18.

119. Sarkar N, Saha B, Singh S, Ghosal S. Tropidia Curculioides: Secondary metabolites and derivatives with antimycobacterial and leishmanicidal activity. Pharmacognosy Magazine. 2018 Oct 1;14(59):535.DOI: 10.4103/pm.pm_196_18.

120. Sinha A, Singh V, Singh S, Yadav S. Proteomic analyses reveal lower expression of TEX40 and ATP6V0A2 proteins related to calcium ion entry and acrosomal acidification in asthenozoospermic males. Life Sci. 2019;218:81-88. doi:10.1016/j.lfs.2018.12.016.

121. Rufai SB, Singh S*. Whole-Genome Sequencing of Two Extensively Drug-Resistant Mycobacterium tuberculosis Isolates from India. Microbiol Resource Announc. 2019Feb 14;8(7). pii: e00007-19. doi: 10.1128/MRA.00007-19

122. Pal R, Hameed S, Kumar P, Singh S, Fatima Z. Understanding lipidomic basis of iron limitation induced chemosensitization of drug-resistant Mycobacterium tuberculosis. 3 Biotech. 2019 Apr;9(4):122. doi: 10.1007/s13205-019-1645-4.

123. Kant K, Tomar AK, Singh S, Yadav S. Ageing associated proteomic variations in seminal plasma of Indian men. Journal of Proteins and Proteomics. 2019 Jun 1; 10(2):83-9. DOI: 10.1007/s42485-019-00013-x.

124. Kant K, Tomar AK, Sharma P, Kundu B, Singh S, Yadav S. Human Epididymis Protein 4 Quantification and Interaction Network Analysis in Seminal Plasma. Protein Pept Lett. 2019 Jul 4; 26(6):458-465. doi: 10.2174/0929866526666190327124919. PubMed PMID: 30919767.

125. Shankar P, Mishra J, Bharti V, Parashar D, Singh S*. Multiplex PCR assay for simultaneous detection and differentiation of Entamoeba histolytica, Giardia lamblia, and Salmonella spp. in the municipality-supplied drinking water. J Lab Physicians. 2019 Jul-Sep;11(3):275-280. doi: 10.4103/JLP.JLP_66_18. PubMed PMID: 31579243; PubMed Central PMCID: PMC6771313.

126. Chauhan V, Singh S, Galwankar S, Aggarwal P, Bhoi S, Di Somma S, Peacock WF, Paladino L. Establishing national centre for point-of-care technology for 'Swasth Bharat, Samridh Bharat'. J Lab Physicians. 2019 Jul-Sep;11(3):177-179. doi: 10.4103/JLP.JLP_139_19. PubMed PMID: 31579259; PubMed Central PMCID: PMC6771327.

127. Rajni E, Ghiya BC, Singh S, Shankar P, Swami T, Jadon DS, Negi SR, Malik M, Khatri PK. Cutaneous leishmaniasis in Bikaner, India: Clinicoepidemiological profile; parasite identification using conventional, molecular methods and CL Detect™ rapid test, a new Food and Drug Administration-approved test. Trop Parasitol. 2019 JulDec;9(2):115-123. doi: 10.4103/tp.TP_1_19. Epub 2019 Sep 18. PubMed PMID: 31579666; PubMed Central PMCID: PMC6767788.

128. Verma T, Podder S, Mehta M, Singh S, Singh A, Umapathy S, Nandi D. Raman spectroscopy reveals distinct differences between two closely related bacterial strains, Mycobacterium indicus pranii and Mycobacterium intracellular. Anal Bioanal Chem. 2019 Dec; 411(30):7997-8009. doi: 10.1007/s00216-019-02197-z. Epub 2019 Nov 16. PubMed PMID: 31732785.

129. Singh S*. Face to face: Leishmaniasis and its changing patterns. Trop Parasitol. 2019 Jul-Dec; 9(2): 133–137. doi: 10.4103/tp.TP_48_19.

130. Jain P, Ojha SK, Kumar V, Bakhshi S, Singh S, Yadav S. Differential seminal plasma proteome signatures of acute lymphoblastic leukemia survivors. Reprod Biol. 2019 Dec; 19(4):322-328. doi: 10.1016/j.repbio.2019.11.002. Epub 2019 Nov 8. PubMed PMID: 31711845.

131. Batra P, Batra M, Singh S*. Epidemiology of TORCH Infections and Understanding the Serology in Their Diagnosis. J. Fetal Med, 2020, 7: 25–29.

132. Sharma V, Makhdoomi M, Singh L, Kumar P, Khan N, Singh S, Verma HN, Luthra K, Sarkar S, Kumar D. Trehalose limits opportunistic mycobacterial survival during HIV co-infection by reversing HIV-mediated autophagy block. Autophagy. 2020 Feb 20:1- 20. doi: 10.1080/15548627.2020.1725374. [Epub ahead of print] PubMed PMID: 32079455.

133. Barr DA, Lewis JM, Feasey N, Schutz C, Kerkhoff AD, Jacob ST, Andrews B, Kelly P, Lakhi S, Muchemwa L, Bacha HA, Hadad DJ, Bedell R, van Lettow M, Zachariah R, Crump JA, Alland D, Corbett EL, Gopinath K, Singh S, Griesel R, Maartens G, Mendelson M, Ward AM, Parry CM, Talbot EA, Munseri P, Dorman SE, Martinson N,Shah M, Cain K, Heilig CM, Varma JK, Gottberg AV, Sacks L, Wilson D, Squire SB, Lalloo DG, Davies G, Meintjes G. Mycobacterium tuberculosis bloodstream infection prevalence, diagnosis, and mortality risk in seriously ill adults with HIV: a systematic review and meta-analysis of individual patient data. Lancet Infect Dis. 2020 Mar 13. pii: S1473-3099(19)30695-4. doi: 10.1016/S1473-3099(19)30695-4. [Epub ahead of print] PubMed PMID: 32178764.

134. Martinez L, Cords O, Horsburgh CR, Andrews JR; Paediatric TB Contact Studies Consortium. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020 Mar 21; 395(10228):973- 984. doi: 10.1016/S0140-6736(20)30166-5. PubMed PMID: 32199484.

135. Rufai SB, Umay K, Singh PK, Singh S*. Performance of Genotype MTBDRsl V2.0 over the Genotype MTBDRsl V1 for detection of second line drug resistance: An Indian perspective. PLoS One. 2020 Mar 4;15(3):e0229419. doi: 10.1371/journal.pone.0229419. eCollection 2020. PubMed PMID: 32130233; PubMed Central PMCID: PMC7055869.

136. Singh S*. Rapid Antibody-based test for the diagnosis of Covid-19: A bigger epidemic of unscientific practice. J Lab Physicians. 2020 March. DOI:http://doi.org/10.1055/s0040-1712711.

137. Singh PK, Kulsum U, Rufai SB, Mudliar SR, Singh S*. Mutations in SARS-CoV-2 Leading to Antigenic Variations in Spike Protein: A Challenge in Vaccine Development. J Lab Physicians. 2020 Aug;12(2):154-160. doi: 10.1055/s-0040- 1715790. Epub 2020 Sep 1. PMID: 32884216; PubMed Central PMCID: PMC7462717.

138. Srivastava S, Verma S, Kamthania M, Agarwal D, Saxena AK, Kolbe M, Singh S, Kotnis A, Rathi B, Nayar SA, Shin HJ, Vashisht K, Pandey KC. Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide. J Biomol Struct Dyn. 2020 Nov 6;:1-20. doi: 10.1080/07391102.2020.1838329. PMID: 33155524; PubMed Central PMCID: PMC7651196.

139. Singh AK, Nema RK, Joshi A, Shankar P, Nema S, Raghuwanshi A, Patankar C, Mathew BJ, Shrivas A, Pandey R, Tripathi R, Biswas D, Singh S. Evaluation of pooled sample analysis strategy in expediting case detection in areas with emerging outbreaks of COVID-19: A pilot study. PLoS One. 2020;15(9):e0239492. doi: 10.1371/journal.pone.0239492. PMID:32960929; PubMed Central PMCID: PMC7508355.

140. Dhingra B, Singh S*. Pneumococcal vaccination in persons living with HIV: Pneumococcal conjugate, polysaccharide or both?. EClinicalMedicine. 2020 Dec;29- 30:100593. doi: 10.1016/j.eclinm.2020.100593. eCollection 2020 Dec. PubMed PMID: 33305195; PubMed Central PMCID: PMC7708955.

141. Papadimos TJ, Soghoian SE, Nanayakkara P, Singh S, Miller AC, Saddikuti V, Jayatilleke AU, Dubhashi SP, Firstenberg MS, Dutta V, Chauhan V, Sharma P, Galwankar SC, Garg M, Taylor N, Stawicki SP. COVID-19 Blind Spots: A Consensus Statement on the Importance of Competent Political Leadership and the Need for Public Health Cognizance. J Glob Infect Dis. 2020 Oct-Dec;12(4):167-190. doi: 10.4103/jgid.jgid_397_20. eCollection 2020 Oct-Dec. PubMed PMID: 33888955; PubMed Central PMCID: PMC8045535.

142. Mangalgi S, Madan K, Das CJ, Singh G, Sati H, Kanwar Yadav R, Xess I, Singh S, Bhowmik D, Agarwal SK, Bagchi S. Pulmonary infections after renal transplantation: a prospective study from a tropical country. Transpl Int. 2021 Mar;34(3):525-534. doi: 10.1111/tri.13817. Epub 2021 Feb 26.PMID: 33423313

143. Sharma V, Makhdoomi M, Singh L, Kumar P, Khan N, Singh S, Verma HN, Luthra K, Sarkar S, Kumar D. Trehalose limits opportunistic mycobacterial survival during HIV co-infection by reversing HIV-mediated autophagy block. Autophagy. 2021 Feb;17(2):476-495. doi: 10.1080/15548627.2020.1725374. Epub 2020 Feb 20.PMID: 32079455

144. Sehgal IS, Guleria R, Singh S, Siddiqui MS, Agarwal R. A randomised trial of Mycobacterium w in critically ill patients with COVID-19: ARMY-1. ERJ Open Res. 2021 Apr 12;7(2):00059-2021. doi: 10.1183/23120541.00059-2021. eCollection 2021 Apr.PMID: 34031642

145. Vishinkin R, Busool R, Mansour E, Fish F, Esmail A, Kumar P, Gharaa A, Cancilla JC, Torrecilla JS, Skenders G, Leja M, Dheda K, Singh S, Haick H. Profiles of Volatile Biomarkers Detect Tuberculosis from Skin. Adv Sci (Weinh). 2021 Aug;8(15):e2100235. doi: 10.1002/advs.202100235. Epub 2021 Jun 2.PMID: 34075714

146. Singh AK, Nema RK, Joshi A, Shankar P, Gupta S, Yadav AK, Nema S, Mathew BJ, Shrivas A, Patankar C, Raghuwanshi A, Pandey R, Tripathi R, Ansari K, Singh K, Yadav J, Biswas D, Singh S*. Testing of four-sample pools offers resource optimization without compromising diagnostic performance of real time reverse transcriptase-PCR assay for COVID-19. PLoS One. 2021 May 18;16(5):e0251891. doi: 10.1371/journal.pone.0251891. eCollection 2021.PMID: 34003869

147. Chauhan K, Soni D, Sarkar D, Karuna T, Sharma B, Singh S, Karkhur S. Mucormycosis after COVID-19 in a patient with diabetes. Lancet. 2021 Aug 21;398(10301):e10. doi: 10.1016/S0140-6736(21)01641-X. Epub 2021 Aug 4.PMID: 34363754

148. Joshi A, Shankar P, Chatterjee A, Singh J, Pakhare A, Yadav K, Shrivas A, Maurya AK, Nagi RS, Biswas D, Kokane AM, Singh S. Heterogeneous patterns of COVID-19 transmission in an Urban set up - sero-epidemiological survey data from Ujjain, Madhya Pradesh (a central Indian city). Data Brief. 2021 May 25;37:107169. doi: 10.1016/j.dib.2021.107169. eCollection 2021 Aug.PMID: 34136600

149. Sikka V, Somma SD, Galwankar SC, Sinha S, Garg N, Talwalkar N, Garg S, Mahajan P, Chauhan V, Moreno-Walton L, Dubhashi S, Dutta V, Saddikuti V, B Nanayakkara PW, Grover J, Paranjape K, Singh S, Sharma P, Bhoi S, Sinha T, Stawicki SP, Garg M, Sardesai I. The World Health Organization Collaborating Center for Emergency and Trauma (WHO-CCET) in South East Asia, The World Academic Council of Emergency Medicine (WACEM), and The American College of Academic International Medicine (ACAIM) 2021 Framework for using Telemedicine Technology at Healthcare Institutions. J Emerg Trauma Shock. 2021 Jul-Sep;14(3):173-179. doi: 10.4103/jets.jets_105_21. Epub 2021 Sep 30. PubMed PMID: 34759635; PubMed Central PMCID: PMC8527056.

150. Singh J, Malhotra AG, Biswas D, Shankar P, Lokhande L, Yadav AK, Raghuvanshi A, Kale D, Nema S, Saigal S, Singh S*. Relative Consolidation of the Kappa Variant PreDates the Massive Second Wave of COVID-19 in India. Genes (Basel). 2021 Nov 16;12(11). doi: 10.3390/genes12111803. PubMed PMID: 34828410; PubMed Central PMCID: PMC8620562.

151. Singh J, Yadav AK, Pakhare A, Kulkarni P, Lokhande L, Soni P, Dadheech M, Gupta P, Masarkar N, Maurya AK, Nema S, Biswas D, Singh S*. Comparative analysis of the diagnostic performance of five commercial COVID-19 qRT PCR kits used in India. Sci Rep. 2021 Nov 10;11(1):22013. doi: 10.1038/s41598-021-00852-z. PubMed PMID: 34759300; PubMed Central PMCID: PMC8580981.


Grants,Awards and Certifications

Grants :

Title

Funding agency

Period

  1. PCR for the Diagnosis of Toxoplasmosis

Developed an in-house PCR kit for the diagnosis of antenatal and acquired Toxoplasmosis. The protocol and primers are being routinely used in diagnostic laboratory.

DBT,  India

1991-1993

  1. TNF-alpha in Malaria

High levels of TNF-a were found in patients with fulminant and cerebral falciparum malaria, as compared to benign malaria. The results are published in peer reviewed journals.

AIIMS

1992-1993

  1. Developing Indigenous ELISA, DAT & Latex agglutination test kits for the diagnosis of Acute Toxoplasmosis.

Developed an in-house modified direct agglutination test kit. The kit is patented in India for the diagnosis of human and animal toxoplasmosis.

DBT, India

 

1996-1999

  1. Are Visceral and post Kala-azar dermal leishmaniases caused by same stain of L. donovani?

This study revealed that VL and PKDL isolates of Leishmania donovani have significant genetic heterogeneity. These isolates also have significant difference in their drug susceptibility patter to standard drugs.  Several papers have been published from the project.

DBT, India

 

1996-2000

  1. Identification of Drug Resistant strain (s) of clinically relevant Mycobacteria specially M. tuberculosis and genes associated with resistance.

A data base was prepared for the first time from North India and several new species and strains of M. tuberculosis were identified. These strains were used as resource by other scientists of the country.

DBT, India

 

1996-2000

  1. Isolation of free living amoeba from AIIMS water supply.

Acanthamoebae were isolated in majority of drinking water samples collected from households. The isolation was significantly higher from the pre-filter collection and overhead tanks. The findings are published.

AIIMS

1996-1999

  1. PCR and Cytokine assays in the diagnosis of visceral leishmaniasis.

This pilot project revealed possibility of animal reservoirs of Indian VL. This hypothesis leads us to plan a bigger study to screen various domestic and wild animals using molecular methods of screening.

ICMR, India

1999-2001

  1. Collection of well-characterized clinical samples for the purpose of evaluation of tests developed by various groups for early detection of M. tuberculosis.

As evident from the title, a repository of Mycobacterial isolates and clinical samples was established. The well characterized isolates and clinical material was/is being sourced out to various other scientists working on TB diagnosis. Several daughter projects were planned out from this resource.

DBT, India

 

1996-2000

  1. Collection of well-characterized clinical samples and strains of M. tuberculosis and development of molecular techniques for the detection of drug resistant strains.

As an offshoot of the previous study, several molecular methods were developed by our laboratory and others. The samples and isolates in our repository were used for evaluation and validation of various tests developed in-house by Indian scientists and also commercially for the diagnosis and detection of drug resistant M. tuberculosis.

DBT, India

 

2000-2003

  1. Base line Database collection and documentation of Good manufacturing and supply practices adopted by the manufacturers of TORCH- ELISA kits and quality control assessment at the user level of these kits.

The study revealed that quality control and Human Resource standards adopted by majority of small and middle-level private laboratories are dismal in India. The recommendations were submitted to Government of India, which in-turn formulated important guidelines and accreditation of these laboratories.

DST, India

2003-2005

  1. Expression, Characterization & purification of recombinant kinesin like protein of VL & PKDL and developing test methods using the above antigen.

A novel recombinant kinesin-like antigen was prepared from an Indian isolate of Leishmania donovani (Ld-rKE16). Invention is patented globally. The technology was transferred to a commercial firm. Using this novel antigen, ELISA and rapid diagnostic test kits are prepared. The kit has 99% sensitivity and 100% specificity. Several national Governments are using this kit. The kit has also been endorsed by WHO.

DBT, India

 

2003-2006

  1. Screening of marine products for in-vitro anti-Mycobacterial activity.

A natural product was found to have anti-mycobacterial activity. The molecule was transferred to a pharmaceutical company for further evaluation.

CSIR, India

2003-2005

  1. Comparative Evaluation of various in-vitro methods for diagnosing pulmonary and extra-pulmonary tuberculosis.

Various microbiological and serological methods were compared for the accurate diagnosis of PTB and EPTB. The results are published in reputed journals. These results helped Government of India to ban the serology.

BioMerieux, India

2004-2007

  1. Rapid and accurate diagnosis of Tuberculosis using a novel set of primers directly from clinical samples.

Various monoplex and a novel multiplex PCR system was developed. The multiplex PCR detects M. tuberculosis, M avium and other NTM in a single tube. The results of validation and cross evaluation are published in reputed journals.

ICMR, India

 

2004-2007

  1. Evaluation of toxicity of Kalsome in Mouse model.

Kalsome is a new form of liposomal amphotericin B being used for the treatment of Leishmaniasis and fungal infections. It uses ergosterol as lipid capsule. A real-time PCR was developed to evaluate the efficacy of this drug. In mice model

DST, India

2005-2007

  1. The role of TNF-α in the success of anti-tubercular therapy in Immune Restoration Disease in HIV/MTB co-infected patients responding to ART.

Aust-Ind Council

2007-2009

  1. Transmission of Drug Resistant Hepatitis B Virus in Close Family Contacts of HBV-Related Chronic Liver Disease Patients.

High rate of transmission was demonstrated in household contacts of Hepatitis B infected source patients. Close contact and clothes were incriminated in the transmission of this virus to contacts.

DST, India

2006-2009

  1. Proteomic analysis of the M. tuberculosis during the stage of acquisition of resistance to the Isoniazid and Rifampicin.

Four Novel proteins are identified which are overexpressed during the acquisition of drug resistance. The results are published in peer reviewed journal. A patent has also been filed.

DBT, India

 

2006-2011

  1. Genotyping of Mycobacterium tuberculosis isolates from Delhi & determining their Transmission Dynamics using Mol. methods.

This community based study showed that a significant number of asymptomatic household contacts of index patients can be diagnosed well before they clinically manifest, using molecular and modern diagnostic tools. The study concluded that contact tracing was most useful of treating and controlling tuberculosis.

ICMR, India

 

2007-2011

  1. A novel multiplexes PCR for simultaneous identification and discrimination of M. tuberculosis complex, M. avium complex and other NTM ....clinical specimens.

This was in continuation of previous study. The novel multiplex PCR developed for the diagnosis and differentiation of M. tuberculosis (novel Esat-6 primers), 16SrRNA and hsp60 was evaluated across the country on various types of clinical samples and standard strains. The PCR was found to be 98% sensitive and 97% specific. The invention is patented in several countries and ready for commercialization.

DBT, India

 

2007-2011

  1. Detection of Hepatitis A, E, Salmonella, E. histolytica and Giardia lamblia from drinking water samples using novel multiplex PCR.

A pentaplex PCR was developed and evaluated for the simultaneous diagnosis of Hepatitis A, E, Salmonella typhi, E. histolytica and Giardia lamblia from drinking water and stool samples. The technology is ready for commercialization.

DBT, India

 

2007-2010

  1. Isolation and purification of active compounds with anti-leishmanial activity from Unani Medicinal Plants

CCRUM, India

2007-2010

  1. Role of Micronutrient Supplementation in Childhood Tuberculosis.

This comprehensive study revealed several new findings that included efficacy of Gene-Xpert in archived gastric aspirate and induced sputum samples; high rate of MDR in paediatric tuberculosis, as compared to adults; better diagnostics tools and algorithms and new biomarkers for childhood tuberculosis. Six papers in high impact journals have been published and many more are in pipeline.

University of Bergen, Norway

2008-2012

  1. Doctor’s Office Diagnostic Instrument for detection of M. tuberculosis

This grant was primarily coordinated by Prof. VK Chaudhary from Delhi University. The innovations are in developmental stage.

Indo-Sweden collaboration

2009-2011

  1. Animal studies on Chimeric Vaccine for the Prophylaxis of Leishmaniasis and Tuberculosis.

A new chimeric vaccine against TB and Leishmania (both) has been developed and the innovation has been patented globally through PCT route. Two papers in high impact journals have been published.

ICMR, India

2010-2014

  1. Cloning Expression purification and evaluation of recombinant antigens for the diagnosis prognosis and prediction of MDR/XDR tuberculosis.

Five novel antigens have been identified and patent has been filed and technology is being considered for transfer for commercialization. Three publications in reputed journals have been published.

ICMR, India

2010-2014

  1.  A novel loop mediated isothermal amplification (LAMP) assay for rapid detection and differentiation of mycobacterium tuberculosis M. avium complex and other mycobacterium species directly from clinical samples.

A novel set of 6 primers and probes has been developed. One publication in reputed journals has been published.

DBT, India

2011-2014

  1. Leishmania kinesisn Motor Domain with BCG as a vaccine formulation against experimental visceral Leishmaniasis.

ICMR, India

2012-2014

  1. Molecular Epidemiology and Genetic Characterization of M. tuberculosis from HIV seronegative and HIV seropositive patients.

No major difference was found in the genotypes of MTB isolated from HIV-TB co-infected patients vis-à-vis HIV uninfected patients.

ICMR, India

2012-2014

  1. Sero-epidemiology of Toxoplasmosis in women of Child bearing Age in India.

One publication in a highly reputed journal has been published. On the basis of this publication which shows several new observations, PI has been invited to deliver talks on Toxoplasmosis within and outside India as guest speaker.

Abbott Health Care, India

2011-2012

  1. A side by side comparison of current gold standard methods for diagnosing tuberculosis from sputum with DNA Genotek chemistries

Genotek/ Imperial Life Sciences, India

2013-2014

  1. Kinetoplastid Drug Development: Strengthening the preclinical pipeline- KINDReD.

Two publications in reputed journals have been published. At least two compounds have been identified as potential drugs against VL and  one compound against CL.

European Commission, Belgium

2013-2016

  1. Molecular Epidemiology & drug resistance pattern of Mycobacterium tuberculosis from North-East region of India

DBT

2014-2017

  1. Medicinal Orchids of Arunachal Pradesh: Micropropagation, phytochemical characterization and biological activity

DBT

2013-2017

  1. Batch Efficacy Testing for Infectious Diseases markers on Advia Centaur system

Siemens India

2014-2017

  1. Evaluation of Adhesive Sensors for the detection of Tuberculosis specific volatile organic compounds

Bill & Melinda Gates foundation with Technion R&D foundation Ltd. Israel

2015-2017

37.Development of Rapid Biosensor Based Diagnostic Test For Tuberculosis

Prospective outcome:

Development of biosensor based rapid diagnostic test for tuberculosis including extra-pulmonary tuberculosis. Four antigens (SS1, SS3, SS4 and SS5) will be selected for the development of Graphene/ CNTs electrode based amperometric sensor-based device for point of care diagnosis of tuberculosis. It will help to explore the commercial utility of these antigens in India or worldwide.

DHR, India

2017- Ongoing

  1. Development of platform technologies for high affinity antibodies for in vitro diagnostics.

Prospective outcome:

The prime focus of the project would be to establish basic platform technologies for production of high affinity antibodies using conventional hybridoma techniques with high-throughput approaches, and involving phage display based technology for producing high affinity recombinant antibodies from immunized mice and rabbits. The work employing rabbit will be the first of its kind in the country. For establishing these technologies, we have aimed at producing immuno-reagents for developing antigen-detection diagnostic tests for Tuberculosis, as model system. The project is expected to deliver rapid tests for the detection of TB. In addition, we propose to develop a strategy to identify antigen-antibody cognate pairs at genome scale again using M. tuberculosis genome as a model system.

DBT, India

2017- Ongoing

  1. Study of the Relative Contributions of Genotypic/Phenotypic Means of Stress Tolerance: Investigation of the Physiology of Mycobacterium tuberculosis Populations of Patient Origin (Project 4 of the COE on- Mechanisms of stress tolerance in M. tuberculosis and its physiological relevance)

Prospective outcome:

In the present study, we showed a dominant role of phagosomal acidification in facilitating heterogeneity in the redox physiology of Mtb to generate an actively replicating, drug-tolerant population exhibiting higher antioxidant capacity (EMSH-reduced) during infection. Our study constitutes an important foundation linking the macrophage environment with the core redox physiology of Mtb to promote drug tolerance in replicating Mtb, a population not typically associated with tolerance.

DBT, India

2017- Ongoing

  1. New Multiplex Blood Based Assay for Diagnosis of Mycobacterium

Prospective outcome:

To determine diagnostic utility of multiplex microbeads immunoassay in TB diagnosis. This assay (RU-1) will be developed using 11 recombinant antigens against M.Tb. The sensitivity and specificity of the RU-1 test will be calculated from plasma samples and DBS (Dried Blood Spot) from patients with pulmonary tuberculosis patients, other respiratory diseases and healthy controls.

NextGen Invitro Diagnostics Pvt. Ltd.

2017- Ongoing

  1. Development of Novel Molecular test for rapid diagnosis of XDR-TB

Prospective outcome:

Development of the test may prove to be more specific than Phenotypic DST/Available molecular test and will be helpful in treatment management of drug resistant tuberculosis by decreasing diagnostic delay.

ICMR, India

2018- Ongoing

  1. Blood test for all forms of active tuberculosis (TB) for commercialization in India

Prospective outcome:

The completion of a validation trial of a novel multiplex serological antibody detection test (RU-1) under the approved directions of Indian Council on Medical Research (ICMR). Upon the completion of the studies in three years this test will seek approval for commercialization in India. It is expected that the necessary approvals will be obtained within six months to begin the commercialization and marketing process. The test contains 11 M.tb. antigens (RU-1) for the detection of all forms of TB including EPTB (Extra-Pulmonary TB) and PED-TB (Paediatric-TB) accurately, efficiently and economically with high sensitivity/specificity. A public/private partnership will be developed between the Indian PI's (Dr. Sarman Singh) clinical laboratory and NextGen In Vitro Diagnostics (NGIVD), New Delhi, a private company, for commercialization of the TB diagnostic product. RU-1 test is low cost, priced at INR500. It has high sensitivity (91%; 96% specificity), which is a major improvement over the front-line test, sputum smear microscopy recommended by WHO, that suffers from low sensitivity (~50%).

DST, India

24.11.2018 to 23.11.2021- Ongoing

43.A Multi-drug Combination (MDC) formulated on the basis of ancient old Science of Ayurveda

Outcome:

The project is designed to evaluate the sensitivity of a multidrug combination Fifatrol (Aimil Pharmaceuticals) and it’s constitutes against various gram positive and gram negative bacteria and also the antimicrobial spectrum for other microbes. Fifatrol is an ancient medicine for modern time which has anti-bacterial activity for various infectious micro-organisms with the combination of five poly phyto mineral and eight active herbal extracts providing the fast relief in fever, nasal congestion, sore throat and body ache. It has also antipyretic, analgesic, anti-infective, anti-oxidant, decongestant, anti-allergic and anti-inflammatory properties and is an immunomodulator. This study will help to find out a new promising drug for many infectious diseases with no side effects and reduced the possibilities of microbes to become resistant for naturally synthesized antibiotics.

AIMIL Pharmaceuticals, India

2018- Waiting for extension

44.Evaluation of Loop Mediated Isothermal Amplification Assay (LAMP) for rapid detection of Mycobacterium tuberculosis from clinical samples

Prospective outcome:

Developed a isothermal based assay for diagnosis of Mycobacterium tuberculosis

 

DBT, India

2018- Waiting for extension

45.Centre  of Learning and Excellence in Advance Nursing (CLEAN) funded by NHM, Directorate of Health Services

Prospective outcome

To train the staff nurse/staff in the various speciality/areas: Trauma Emergency, Operation theatre, Intensive care ICU, Haemo-dialysis and Cancer care

 

NHM, MP Govt.

12.12.2018 to 11.12.2021

 

  1. Comprehensive OMICS studies to understand the biology of drug resistant Mycobacterium tuberculosis clinical isolates from Arunachal Pradesh

Prospective outcome:

The study at genome, proteome and lipidome scale of the drug resistant Mycobacterium tuberculosis isolates from Arunachal Pradesh will open new vistas to drive biological discovery in the TB research field by providing scaffolding for the interpretation of “omic” scale datasets, directing hypothesis that presence of some novel/unique genes or pathways in different geno-lineages such as Beijing make them more virulent and resistant to anti-tubercular drugs and also assisting in the identification of novel drug and diagnostic targets. Evolutionary relationship among drug resistant and sensitive strains will help in development of potential candidates for vaccine/diagnostics for TB.

DBT, India

2019- Ongoing

  1. Toxoplasma gondii: Seroprevalence, associated risk factors, genotyping and Pregnancy outcome in tea tribe population of Assam funded by DBT

Prospective outcome: It will detect the sero-prevalence of the Toxoplasma gondii infection in female of tea tribe population of the North East (Assam). And associated risk factors, genotyping and pregnancy outcome in the selected population.

DBT, India

11.01.2019 to 10.01.2022

  1. Intensified Pulmonary Tuberculosis case finding among selected high risk clinical groups attending secondary level public health care facilities

(Yet to start)

ICMR, India

2020- Due to COVID- 19, Recruitment process is pending

Awards & Prizes :

  1. Pride of India Award (for Covid-Management), Public Relation Society of India, New Delhi, 2021
  2. Received S.C. Dutt Memorial Oration Award of Indian Association of Veterinary Parasitologists (IAVP), Jabalpur, 2020.
  3. Received Prof. TD Chugh Award of National Academy of Medical Sciences (India), 2019.
  4. Received NAMS Amritsar Oration Award of National Academy of Medical Sciences (India), 2019.
  5. Received Foundation Day Oration Award of National Institute for Research in Environmental Health (NIREH), Bhopal, 2019.
  6. Received AIIMS Research Excellence Award for published work on Tuberculosis, September, 2017.
  7. Received Senior Scientist Oration Award of Indian Immunology Society, at the 43rd IIS Conference at Visakhapatnam, February 2017
  8. Received AIIMS Research Excellence Award for best published work, September 2016 (for Research in Tuberculosis) from Minister of Health & Family Welfare, Government of India.
  9. Received Dr. APJ Abul Kalam Lifetime Achievement Award of Society of Bio- Medical Laboratory Scientists, 2016.
  10. Received Research Excellence Award 2015, Indus Foundation, USA/India, November 2015.
  11. Received BMJ Excellence Award 2014 (India) for Innovation in Healthcare Technology.
  12. Received Med-Achiever Award of Indian Medical Association for Innovative Research, July 2014.
  13. Received Chikitsa Ratna Award of Delhi Medical Association, June 2014.
  14. Received Life Time Achievement Award of the Society for Immunology & Immunopathology, December 2013.
  15. Received Prof. BK Aikat Oration Award of Indian Council of Medical Research, 2008 for his original work on Kala-Azar.
  16. Received BC Roy Award (Hari Om Ashram Alembic Research Award) of Medical Council of India, for the year 2007.
  17. Received Vigyan Ratna Samman awarded by Council of Science and technology, Government of UP, for the year 2006.
  18. Received Biotechnology Product, Process and Commercialization Award for Commercialization of a novel recombinant antigen of Leishmania donovani for the accurate diagnosis of Kala-azar and PKDL. 2006.
  19. Received Prof. BP Pandey Memorial Oration Award for Best Teacher in Parasitology, Indian Society for Parasitology 2006.
  20. Received Merit Award 1998 of the International Immunocompromised Host Society (USA), June 1998, Davos (Switzerland).
  21. Received ICMR Award for the work on Parasites in general and Toxoplasma gondii in particular by the Indian Council of Medical Research, 1996.
  22. Received Young Scientist Award 1996 of the International Immunocompromised Host Society (USA), June 1996, Assisi (Italy).
  23. Biotechnology Long Term Overseas Associateship for 1 year Awarded by the Ministry of Science and Technology, Government of India, to work in USA, 1994-95
  24. Received Best Citizen Award of the Best Citizen Publishing House (Delhi) for year 2006
  25. Received “Man of the Year 1998” by the American Biographical Institute, Raleigh, USA.
  26. Received First prize in Hindi dictation by any faculty member at AIIMS, New Delhi for year 2006.
  27. Task Force Member of SERC (FAST TRACK SCHEME) of Department of Science and Technology, Government of India. 2004-2007 & again for 2008-2011.
  28. Elected Consulting Editor of The contemporary "Who's Who" (USA). 2003.
  29. Elected Member of  Research Advisory Board 1999,  American Biographical Institute,    Raleigh, USA
  30. Elected Member of the New York Academy of Sciences, USA, 1997.
  31. Awarded Full Scholarship from UNAIDS/Canada Government to present a paper in the XI International Conference on AIDS, Vancouver, July 1996.
  32. Awarded Japan Government Full Scholarship to present a paper in the X International Conference on AIDS/STD, August 1994.
  33. Awarded Young Scientist INSA travel grant to present a paper in the VII International AIDS Conference, June 1991, Italy.
  34. Awarded Young Scientist DST travel grant to attend the VII International AIDS Conference, June 1991, Italy.
  35. Awarded CSIR travel award for obtaining training in Epidemiology of Infectious Diseases, University of Michigan, USA, 1990.


Languages

Language Proficiency :

English (Excellent Spoken and Written)

Translation Services :

Hindi (Sanskritised Hindustani) to English (Excellent Spoken and Written)